Auro Laboratories Ltd

₹ 227 -2.89%

25 Aug 4:01 p.m.

About

Incorporated in 1989, Auro Laboratories Ltd is in the business of Bulk Drugs^[1]

Key Points

Business Overview:^[1]^[2]
Auro Laboratories Limited manufactures generic APIs, primarily Metformin Hydrochloride for type 2 diabetes. It operates an approved manufacturing facility with Indian regulatory approvals and European registrations, has expanded production capacity, and also undertakes toll and custom manufacturing of APIs and intermediates on a contract basis.

Website BSE

Market Cap ₹ 142 Cr.
Current Price ₹ 227
High / Low ₹ 317 / 159
Stock P/E 64.3
Book Value ₹ 69.9
Dividend Yield 0.00 %
ROCE %
ROE 4.28 %
Face Value ₹ 10.0

Add ratio to table

Edit ratios

Pros

Cons

Stock is trading at 3.25 times its book value
Company has high debtors of 177 days.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals

Edit Columns

Loading peers table ...

Detailed Comparison with:

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

	Sep 2024	Jun 2025	Sep 2025
	3.10	2.77	8.84
	2.38	2.74	6.49
Operating Profit	0.72	0.03	2.35
OPM %	23.23%	1.08%	26.58%
	0.31	0.42	0.98
Interest	0.28	0.28	0.96
Depreciation	0.27	0.27	0.65
Profit before tax	0.48	-0.10	1.72
Tax %	25.00%	0.00%	58.14%
	0.36	-0.11	0.72
EPS in Rs	0.58	-0.18	1.16
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

	Mar 2025
	19.40
	16.00
Operating Profit	3.40
OPM %	17.53%
	0.66
Interest	1.08
Depreciation	1.10
Profit before tax	1.88
Tax %	2.13%
	1.84
EPS in Rs	2.95
Dividend Payout %	0.00%

Compounded Sales Growth
10 Years:	%
5 Years:	%
3 Years:	%
TTM:	%

Compounded Profit Growth
10 Years:	%
5 Years:	%
3 Years:	%
TTM:	%

Stock Price CAGR
10 Years:	22%
5 Years:	12%
3 Years:	28%
1 Year:	-7%

Return on Equity
10 Years:	%
5 Years:	%
3 Years:	%
Last Year:	4%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

	Mar 2025	Sep 2025
Equity Capital	6.23	6.23
Reserves	36.74	37.35
	42.72	43.94
	13.41	23.25
Total Liabilities	99.10	110.77
	21.05	76.84
CWIP	56.48	10.37
Investments	0.05	0.05
	21.52	23.51
Total Assets	99.10	110.77

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

	Mar 2025



Net Cash Flow
Free Cash Flow
CFO/OP

Ratios

Consolidated Figures in Rs. Crores / View Standalone

	Mar 2025
Debtor Days	176.67
Inventory Days	145.45
Days Payable	246.11
Cash Conversion Cycle	76.01
Working Capital Days	-14.30
ROCE %

Insights

In beta

Mar 2015

Mar 2016

Mar 2017

Mar 2018

Mar 2019

Mar 2020

Mar 2021

Mar 2022

Mar 2023

Mar 2024

Mar 2025

Production Volume (API)
kg ・Standalone data

x,xxx,xxx	x,xxx,xxx	x,xxx,xxx	x,xxx,xxx	x,xxx,xxx	x,xxx,xxx	x,xxx,xxx	x,xxx,xxx	x,xxx,xxx	x,xxx,xxx	xxx,xxx
				xx	xx	xx	xx	xx	xx	xx
				xx.xx	xx.xx		xx.xx	xx.xx	xx.xx	xx.xx
	xx	xx	xx	xx					xx	xx
			xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
								x,xxx	x,xxx	x,xxx
					xx	xx

Please log in to see hidden values.

Metformin HCL Share of Revenue
% ・Standalone data

Export Share of Revenue
% ・Standalone data

Number of Permanent Employees
count ・Standalone data

Customer Concentration (Top Customers as % of Revenue)
% ・Standalone data

Installed Capacity (Metformin HCL)
MTPA ・Standalone data

Capacity Utilization
% ・Standalone data

Extracted by Screener AI

Shareholding Pattern

Numbers in percentages

	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
	52.09%	52.09%	52.15%	52.15%	52.15%	52.15%	52.17%	52.17%	52.17%	52.17%	52.17%	52.40%
	0.01%	0.01%	0.01%	0.01%	0.01%	0.01%	0.01%	0.01%	0.01%	0.01%	0.01%	0.01%
	47.92%	47.90%	47.85%	47.84%	47.84%	47.84%	47.82%	47.82%	47.82%	47.80%	47.82%	47.58%
No. of Shareholders	10,272	9,905	9,441	9,335	9,266	9,265	9,102	8,916	8,860	8,640	8,405	8,315

	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026	Jun 2026
	51.23%	51.52%	51.89%	51.92%	51.92%	51.99%	52.09%	52.15%	52.17%	52.17%	52.40%
	0.01%	0.01%	0.01%	0.01%	0.01%	0.01%	0.01%	0.01%	0.01%	0.01%	0.01%
	48.76%	48.47%	48.10%	48.07%	48.07%	48.00%	47.90%	47.85%	47.82%	47.82%	47.58%
No. of Shareholders	7,260	7,375	7,205	7,177	9,151	11,340	10,906	9,441	9,102	8,405	8,315

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Auro Laboratories Ltd

Auro Laboratories Ltd

Peer comparison

Quarterly Results

Profit & Loss

Balance Sheet

Cash Flows

Ratios

Insights

Shareholding Pattern

Documents

Announcements

Annual reports

Credit ratings